Literature DB >> 16125217

Array comparative genomic hybridization analysis of uterine leiomyosarcoma.

Young Lae Cho1, SuMi Bae, Myeong Suk Koo, Kyung Mee Kim, Heung-Jae Chun, Chong Kook Kim, Duck Young Ro, Jang Heub Kim, Chang-Hun Lee, Yong-Wan Kim, Woong Shick Ahn.   

Abstract

PURPOSE: Using a genome-wide array-based comparative genomic hybridization (array-CGH), DNA copy number changes in uterine leiomyosarcoma were analyzed.
MATERIALS AND METHODS: We analyzed 4 cases of uterine leiomyoma and 7 cases of uterine leiomyosarcoma. The paraffin-fixed tissue samples were microdissected under microscope and DNA was extracted. Array-based CGH and fluorescence in situ hybridization (FISH) were carried out with Genome database (Gene Ontology).
RESULTS: Uterine leiomyoma showed no genetic alterations, while all of 7 cases of uterine leiomyosarcoma showed specific gains and losses. The percentage of average gains and losses were 4.86% and 15.1%, respectively. The regions of high level of gain were 7q36.3, 7q33-q35, 12q13-12q15, and 12q23.3. And the regions of homozygous loss were 1p21.1, 2p22.2, 6p11.2, 9p21.1, 9p21.3, 9p22.1, 14q32.33, and 14q32.33 qter. There were no recurrent regions of gain, but recurrent regions of loss were 1p21.1-p21.2, 1p22.3-p31.1, 9p21.2-p22.2, 10q25-q25.2, 11q24.2-q25, 13q12-q12.13, 14q31.1-q31.3, 14q32.32-q32.33, 15q11-q12, 15q13-q14, 18q12.1-q12.2, 18q22.1-q22.3, 20p12.1, and 21q22.12-q22.13. In the high level of gain regions, BAC clones encoded HMGIC, SAS, MDM2, TIM1 genes. Frequently gained BAC clone-encoded genes were TIM1, PDGFR-beta, REC Q4, VAV2, FGF4, KLK2, PNUTL1, GDNF, FLG, EXT1, WISP1, HER-2, and SOX18. The genes encoded by frequently lost BAC clones were LEU1, ERCC5, THBS1, DCC, MBD2, SCCA1, FVT1, CYB5, and ETS2/E2. A subset of cellular processes from each gene was clustered by Gene Ontology database.
CONCLUSION: Using array-CGH, chromosomal aberrations related to uterine leiomyosarcoma were identified. The high resolution of array-CGH combined with human genome database would give a chance to find out possible target genes present in the gained or lost clones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125217     DOI: 10.1016/j.ygyno.2005.07.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  18 in total

1.  Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.

Authors:  Mohammad Raish; Mohsin Khurshid; Mushtaq Ahmad Ansari; Pankaj Kumar Chaturvedi; Su-Mi Bae; Jang Heub Kim; Eun Kyung Park; Dong Chun Park; Woong Shick Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

2.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

3.  Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.

Authors:  Eytan Ben-Ami; Constance M Barysauskas; Sarah Solomon; Kadija Tahlil; Rita Malley; Melissa Hohos; Kathleen Polson; Margaret Loucks; Mariano Severgnini; Tara Patel; Amy Cunningham; Scott J Rodig; F Stephen Hodi; Jeffrey A Morgan; Priscilla Merriam; Andrew J Wagner; Geoffrey I Shapiro; Suzanne George
Journal:  Cancer       Date:  2017-04-25       Impact factor: 6.860

4.  Identification of key genes and pathways in uterine leiomyosarcoma through bioinformatics analysis.

Authors:  Yuqin Zang; Lina Gu; Yanfang Zhang; Yingmei Wang; Fengxia Xue
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

5.  Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.

Authors:  Dimitra Dafou; Barbara Grun; John Sinclair; Kate Lawrenson; Elizabeth C Benjamin; Estrid Hogdall; Susanne Kruger-Kjaer; Lise Christensen; Heidi M Sowter; Ahmed Al-Attar; Richard Edmondson; Stephen Darby; Andrew Berchuck; Peter W Laird; C Leigh Pearce; Susan J Ramus; Ian J Jacobs; Simon A Gayther
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

6.  Gene expression signatures of primary and metastatic uterine leiomyosarcoma.

Authors:  Ben Davidson; Vera Maria Abeler; Mette Førsund; Arild Holth; Yanqin Yang; Yusuke Kobayashi; Lily Chen; Gunnar B Kristensen; Ie-Ming Shih; Tian-Li Wang
Journal:  Hum Pathol       Date:  2013-11-13       Impact factor: 3.466

7.  Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masako Ishiguro; Teruto Isayama; Masatoshi Naito
Journal:  J Exp Clin Cancer Res       Date:  2010-11-24

Review 8.  Aggressive angiomyxoma with t(12;21) and HMGA2 rearrangement: report of a case and review of the literature.

Authors:  Neil J Rawlinson; William W West; Marilu Nelson; Julia A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2008-03

9.  The development of a mini-array for estimating the disease state of gastric adenocarcinoma by array CGH.

Authors:  Tomoko Furuya; Tetsuji Uchiyama; Atsushi Adachi; Takae Okada; Motonao Nakao; Atsunori Oga; Song-Ju Yang; Shigeto Kawauchi; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2008-12-30       Impact factor: 4.430

10.  Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.

Authors:  Josefin Fernebro; Ana Carneiro; Anders Rydholm; Henryk A Domanski; Anna Karlsson; Ake Borg; Mef Nilbert
Journal:  Sarcoma       Date:  2009-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.